{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:32:37Z","timestamp":1785465157349,"version":"3.56.0"},"reference-count":29,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"University of Otago, Wellington","award":["Publication Fees award"],"award-info":[{"award-number":["Publication Fees award"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,4,28]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Vaccination is a public health strategy that aims to reduce the burden of viral illness, especially important for populations known or likely to be at increased risk for inequitable outcomes due to the disease itself or disparities in care accessed and received. The role of weight status in COVID-19 susceptibility and disease burden remains unclear. Despite this, higher weight is frequently described as a definitive risk factor for both susceptibility and disease severity. Therefore, COVID-19 vaccine trials should recruit a study group representative of the full weight spectrum, and undertake appropriate subgroup analysis by weight status to evaluate response and titrate dose regimes where indicated to ensure equitable outcomes for higher weight people.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>We aim to review inclusion and exclusion criteria of clinical trial protocols registered with ClinicalTrials.gov, ISRCTN Register, the WHO official vaccine trial register, and \u2018The COVID-19 Vaccine Tracker\u2019. To determine the number of trials including higher weight (body mass index &gt;30 kg\/m<jats:sup>2<\/jats:sup>) individuals and the number of trials conducting efficacy subgroup analyses by weight status. Screening, data extraction and quality appraisal of trial protocols will be completed independently by a minimum of two reviewers. Clinical trials will be assessed for risk of bias using the Risk of Bias-2 tool. We will conduct a descriptive analysis of extracted data. The following subsets are proposed: participation of higher weight people in COVID-19 vaccine trials by trial phase, country and vaccine platform.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>Ethical approval was not required for this review. The results of this rapid review will be presented at appropriate conferences and published in a suitable peer reviewed journal.<\/jats:p><\/jats:sec><jats:sec><jats:title>PROSPERO registration number<\/jats:title><jats:p>CRD42020226573<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2021-050114","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T16:38:15Z","timestamp":1621960695000},"page":"e050114","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Equity in vaccine trials for higher weight people? Protocol for a rapid review of inclusion and exclusion criteria for higher weight people in clinical trials for COVID-19"],"prefix":"10.1136","volume":"11","author":[{"given":"Jessica","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"O\u2019Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Heywood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6414-3236","authenticated-orcid":false,"given":"Lesley","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"2024102810021004000_11.5.e050114.1","doi-asserted-by":"publisher","DOI":"10.1016\/s01406736(20)30211-7"},{"key":"2024102810021004000_11.5.e050114.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0146736(20)30183-5"},{"key":"2024102810021004000_11.5.e050114.3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa576"},{"key":"2024102810021004000_11.5.e050114.4","unstructured":"Yang J , Zheng Y , Gou X , et al . Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 2020;10."},{"key":"2024102810021004000_11.5.e050114.5","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2020-214297"},{"key":"2024102810021004000_11.5.e050114.6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"TT","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2024102810021004000_11.5.e050114.7","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.dsx.2020.07.022","article-title":"Vaccine development against coronavirus (2003 to present): an overview, recent advances, current scenario, opportunities and challenges","volume":"14","author":"Badgujar","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"2024102810021004000_11.5.e050114.8","unstructured":"Federal Drug Administration . Vaccines and related biological products Advisory Committee. [Internet], 2020. Available: https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/vaccines-and-related-biological-products-advisory-committee-december-17-2020-meeting-announcement#event-materials"},{"key":"2024102810021004000_11.5.e050114.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.04.022"},{"key":"2024102810021004000_11.5.e050114.10","doi-asserted-by":"crossref","unstructured":"Bennet BM , Wolf J , Laureano R , et al . Review of current vaccine development strategies to prevent coronavirus disease 2019 (COVID-19). Toxicol Pathol 2020;0192623320959090.","DOI":"10.1177\/0192623320959090"},{"key":"2024102810021004000_11.5.e050114.11","doi-asserted-by":"crossref","DOI":"10.1055\/s-0040-1712103","article-title":"Exclusion of pregnant women from clinical trials during the coronavirus disease 2019 pandemic: a review of international registries","volume":"37","author":"Smith","year":"2020","journal-title":"Am J Perinatol"},{"key":"2024102810021004000_11.5.e050114.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12368"},{"key":"2024102810021004000_11.5.e050114.13","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/annonc\/mdy138","article-title":"Representation of obese participants in obesity-related cancer randomized trials","volume":"29","author":"Pestine","year":"2018","journal-title":"Annals of Oncology"},{"key":"2024102810021004000_11.5.e050114.14","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13923"},{"key":"2024102810021004000_11.5.e050114.15","unstructured":"Omer S , Faden R , Kochhar S , et al . Who SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of limited supply. World Heal Organ, 2020."},{"key":"2024102810021004000_11.5.e050114.16","doi-asserted-by":"crossref","unstructured":"Zimmermann P , Curtis N . Factors that influence the immune response to vaccination. Clin Microbiol Rev 2019;32.doi:10.1128\/CMR.00084-18","DOI":"10.1128\/CMR.00084-18"},{"key":"2024102810021004000_11.5.e050114.17","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1016\/j.vaccine.2015.06.101","article-title":"The weight of obesity on the human immune response to vaccination","volume":"33","author":"Painter","year":"2015","journal-title":"Vaccine"},{"key":"2024102810021004000_11.5.e050114.18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/oby.23131","article-title":"COVID-19 Vaccination and Obesity: Optimism and Challenges.\"","volume":"27","author":"Townsend","year":"2021","journal-title":"Obesity"},{"key":"2024102810021004000_11.5.e050114.19","unstructured":"Federal Drug Administration . Vaccines and related biological products Advisory Committee Meeting February 26, 2021 FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. [Internet], 2021. Available: https:\/\/www.fda.gov\/media\/146217\/download"},{"key":"2024102810021004000_11.5.e050114.20","unstructured":"Garritty C , Gartlehner G , Kamel C , et al . Cochrane rapid reviews interim guidance from the Cochrane rapid reviews methods group, 2020."},{"key":"2024102810021004000_11.5.e050114.21","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-015-0163-7","article-title":"All in the family: systematic reviews, rapid reviews, scoping reviews, realist reviews, and more","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2024102810021004000_11.5.e050114.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"key":"2024102810021004000_11.5.e050114.23","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2024102810021004000_11.5.e050114.24","unstructured":"London School of Hygiene and Tropical Medicine . VaC COVID-19 vaccine tracker [Internet], 2020. Available: https:\/\/vac-lshtm.shinyapps.io\/ncov_vaccine_landscape\/%0A"},{"key":"2024102810021004000_11.5.e050114.25","unstructured":"ISRCTN Register . ISRCTN Registery [Internet]. Available: http:\/\/www.isrctn.com\/search"},{"key":"2024102810021004000_11.5.e050114.26","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile APP for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2024102810021004000_11.5.e050114.27","unstructured":"Elmagarmid A , Fedorowicz Z , Hammady H . Rayyan: a systematic reviews web APP for exploring and filtering searches for eligible studies for Cochrane reviews. in: Abstracts of the 22nd Cochrane Colloquium. John Wiley & Sons, 2014: 9."},{"key":"2024102810021004000_11.5.e050114.28","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"2","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2024102810021004000_11.5.e050114.29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD201601"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-050114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T17:11:47Z","timestamp":1730135507000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-050114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,25]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/bmjopen-2021-050114"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-050114","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}